Three novel pyrimidinylhydrazones substituted at either the aromatic moiety or at the imine carbon atom were synthesized and characterized by standard analytical methods. All compounds were found to be toxic in the micro-to submicromolar range against a diverse panel of cancer cell lines including multidrug resistant (MDR) derivatives expressing P-glycoprotein (Pgp). UV-visible spectrophotometry experiments demonstrated that the most active compound (3) forms highly stable complexes with iron(III) and copper(II) in a wide pH range with a stronger preference towards iron(III). The redox activity of the iron and copper complexes of ligand 3 was investigated using cyclic voltammetry and was tested with cellular reductants. The impact of reactive oxygen species (ROS) on the mechanism of toxicity was assessed using the ROS-sensitive cell permeable dye 2′,7′-dichlorofluorescin diacetate (DCFDA). Our results demonstrate that the studied pyrimidinylhydrazones form redox-active iron and copper complexes that are capable of producing intracellular ROS, which might lead to cellular damage and cell death in cancer cells regardless of their resistance status.
Introduction
The cellular homeostasis of metals is tightly regulated. As a result, only a minor fraction of the intracellular pools is freely available, and the majority of metal ions are bound to storage proteins or enzymes that utilize them as cofactors or as structural support elements [1, 2] . It is estimated that at least one third of the human proteome consists of metalloproteins, many of which have been associated with various pathological conditions including infectious, cardiovascular and neurodegenerative diseases [3, 4] . As compounds that can directly target the metal ion cofactors of metalloproteins are expected to have a significant biological effect, the development of chelators is a promising strategy in medicinal chemistry. Chelators have been traditionally used for the treatment of metal overload and diseases related to imbalanced metal homeostasis including hemochromatosis, β-thalassemia, and Alzheimer's or Parkinson's diseases [5, 6] . Several studies have described the deregulation of iron homeostasis in cancer, suggesting that the altered metal homeostasis of cancer cells represents a vulnerability that can be targeted by chelation strategies [7, 8] . Cancer cells increasingly rely on iron due to the crucial role of metalloproteins in proliferation. Since metal homeostasis is tightly linked to the regulation of the intracellular redox balance, anticancer metal complexes can also target cancer cells by the formation of redox active complexes giving rise to reactive oxygen species (ROS) [5, 8] .
Examples of chelators with antitumor potential include aroyl-and arylhydrazones, and variously substituted thiosemicarbazones [9] [10] [11] [12] [13] [14] [15] . The proposed mechanism of action of these antibacterial and anticancer compounds is linked to the inhibition of the iron-requiring enzyme ribonucleotide reductase (RR) [5, 8] , the rate determining enzyme supplying deoxyribonucleotides for DNA synthesis [16] . The mammalian enzyme consists of two subunits: R1 harbors the catalytically active center; R2 contains a tyrosyl radical and a diiron center [17] . Compounds targeting RR include antimetabolites such as gemcitabine, scavengers of the tyrosyl radical (hydroxyurea), gallium(III) complexes and various chelators. Triapine, a tridentate α-N-pyridyl thiosemicarbazone is a potent RR inhibitor currently undergoing phase I and II clinical trials [18] [19] [20] . Unfortunately, Triapine is subject to multidrug resistance (MDR), as it is recognized by the ATP-binding cassette (ABC) transporter P-glycoprotein (Pgp/ABCB1) [21] . MDR is a major obstacle in the treatment of cancer. Hence, there is an urgent need for new strategies aiming to overcome MDR [22] . Numerous metal complexes have been developed with the aim of bypassing or even targeting MDR, while minimizing the side effects of clinically used platinum complexes [23] . 1 H NMR and 13 C NMR spectra were obtained on either a Bruker Advance 300 or 500 spectrometer, respectively. DMSO-d 6 or CDCl 3 were used as solvents. Standard pulse programs were applied. Chemical shifts are expressed in ppm values using the residual solvent peaks as internal standards (DMSOd 6 2.50; 39.52 ppm or CDCl 3 7.26; 77.16 ppm) [28] . 13 C NMR signals were assigned with the aid of attached proton test (APT) spectra. Elemental analyses of the final products were performed on a Vario EL elemental analyzer (Hanau, Germany). The values for carbon, nitrogen and hydrogen are given in percentage. Electrospray ionization-mass spectrometry (ESI-MS) measurements for the characterization of the final products were carried out with a Waters Q-TOF Premier instrument (Waters Kft., Hungary) operating in positive ion mode; the samples were dissolved in methanol.
4-Chloro-6-methoxypyrimidine
To a cooled solution (−10°C) of 4,6-dichloropyrimidine (1193-21-1, 5 g, 33.56 mmol) in dry methanol, one equivalent of sodium hydride (titrated solution in dry methanol) was added, the solution was allowed to warm to room temperature and react for 48 h (depicted in step a of Scheme 1). The solvent was removed; the crude product was dissolved in brine, extracted with CHCl 3 , and was used without further purification. 1 
4-Hydrazinyl-6-methoxypyrimidine
To a solution of the 4-chloro-6-methoxypyrimidine, obtained as described in Section 2.2.1 (2.5 g crude product), in methanol an aqueous solution of hydrazine (80%, 6.1 mL) was added and refluxed (see step b of Scheme 1). After evaporation of the solvent, the aqueous solution of the crude product was alkalized with NaOH and extracted with methylene chloride to give the product as an ochre powder in 60% yield. 1 
5-Ethyl-2-methyl-pyridine-N-oxide
35 mL of hydrogen peroxide (35% solution, 0.41 mol) was added to a solution of 5-ethyl-2-methyl-pyridine (104-90-5, 21.76 mL, 0.17 mol) in glacial acetic acid (200 mL) and refluxed for 16 h (depicted in step c of Scheme 1). After evaporation of the majority of the solvent, the reaction mixture was neutralized with NaOH and Na 2 CO 3 and the starting material was retrieved by extraction with petroleum ether. 5-Ethyl-2-methyl-pyridine-N-oxide was extracted from the aqueous phase with CHCl 3 , dried over Na 2 SO 4 and after removal of the solvent obtained as a bright yellow liquid in 99% yield. 1 
5-Ethylpyridin-2-yl-methyl acetate
As depicted in step d of Scheme 1, a solution of the 5-ethyl-2-methylpyridine-N-oxide, obtained in Section 2.2.5 (22.28 g, 0.16 mol), and acetic anhydride (28 mL, 0.23 mol) in glacial acetic acid (7 mL) was refluxed for 3 h, put on ice, neutralized, extracted with methylene chloride. After removal of the solvent, the extract was dissolved in diethyl ether, washed with a saturated solution of Na 2 CO 3 and dried over Na 2 SO 4 to give the product in 85% yield. 1 
5-Ethylpyridin-2-yl-methanol
As depicted in step e of Scheme 1, 5-ethylpyridin-2-yl-methyl acetate (24.29 g, 0.14 mol) was dissolved in tetrahydrofuran (THF) and refluxed with an aqueous solution of NaOH (8.1 g, 0.20 mol) for 5 h. The reaction mixture was reboiled on activated charcoal and was neutralized with glacial acetic acid and filtered. After concentration of the crude product under reduced pressure, it was dissolved in a saturated solution of NaHCO 3 , extracted with diethyl ether and dried over sodium sulfate to give the product as a brown oil in 80% yield. 
5-Ethylpicolinaldehyde
As depicted in step f of Scheme 1, MnO 2 was prepared freshly by simultaneously adding a solution of MnSO 4 hydrate (14.5 g, 0.09 mol in 25 mL water) and NaOH (7.6 g, 2.21 mol in 20 mL water) to a warm solution of KMnO 4 (15.5 g, 0.10 mol in 100 mL water), refluxing the mixture for 6 h, filtered and dried under reduced pressure. 5-Ethylpyridin-2-yl-methanol (12.82 g, 93.4 mmol) was dissolved in chloroform and given to the dried MnO 2 (16.24 g, 186.8 mmol). The mixture was refluxed in an ultrasonic bath for 5 days, filtered and purified with column chromatography using a mixture petroleum ether and ethyl acetate (4:1) on silica gel to give the product as a bright yellow liquid in 61% yield. of about 1 μg/mL. The mass spectrometer was scanned in MRM mode; the Q1/Q3 transitions were as follows: (1) consisting of a binary pump, an autosampler and a column oven) was used for separation. Gemini C18 110A 150 × 4.6 mm, 5 μm was used at 40°C. The mobile phases were: A: 20 mM ammonium formate at pH = 10 adjusted by ammonia (pH = 10 was selected based on the log D versus pH curve. At pH = 10, the compounds are present in neutral form, see Section 3.3); B: methanol. Flow rate was 1 mL/min. The retention times of the compounds were measured at 45, 50, 55, 60 and 65% methanol for the accurate determination of log k (retention factor). Data acquisition was stopped after the elution of the last sample. A 15 minute equilibration step was used prior to the start of the runs at each solvent composition.
The reduced retention time was calculated using the following equation: k = (t 0 − t) / t 0 . Uracil was used for the exact determination of t 0 . The retention time of uracil was 2.2 min at each solvent composition. The log k values of the different eluent composition runs were expressed as the function of the methanol content of the eluent, and extrapolated to pure water for the determination of log Kw.
UV-Vis spectrophotometry
The pH-metric measurements for determination of the exact concentrations of HCl and KOH stock solutions used for the spectrophotometric titrations were carried out at 25.0 ± 0.1°C in aqueous solutions containing 0.5% (v/v) DMSO and at an ionic strength of 0.20 M KCl in order to keep the activity coefficients constant. All the titrations were performed with carbonate-free KOH solutions of known concentration (0.10 M) in the presence of 0.1 M KCl. An Orion 710A pH-meter equipped with a Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 Dosimat burette were used for the pH-metric titrations. The electrode system was calibrated to the pH = − log[H + ] scale by means of blank titrations (strong acid vs. strong base; HCl vs. KOH) according to the method suggested by Irving et al. [29] . The average water ionization constant, pK water , is 13.76 ± 0.01 at 25°C, which corresponds well to the literature data [30] . Samples were deoxygenated by bubbling purified argon for ca. 10 min prior to the measurements and argon was also passed over the solutions during further titrations. A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-Vis spectra in the 200-800 nm interval. The path length was 1 cm. The spectrophotometric titrations were performed on samples of ligand 3 alone or with Fe(III) or Cu(II). The concentration of the ligand was usually 0.05 mM and the metal-to-ligand ratios were 1:1 and 1:2 over the pH range between 2 and 11.5 at an ionic strength of 0.20 M (KCl) at 25.0 ± 0.1°C. The initial volume of the samples was 10.00 mL. Measurements for 1:1 ligand-to-Fe(III) system were also carried out by preparing individual samples in which KCl was partially or completely replaced by HCl. pH values, varying in the range ca. 0.7-2.0, were calculated from the HCl content.
Protonation constants of ligand 3, the stability constants of its metal complexes and the individual spectra of the species were calculated by the computer program PSEQUAD [31] and literature data were used for Fe(III) hydroxido species [32] 
r where M denotes the metal ion and L the completely deprotonated ligand. The calculations were always made from the experimental titration data measured in the absence of any precipitate in the solution.
Electrochemical studies
Cyclic voltammograms of the Fe(III) and Cu(II) complexes were determined at 25.0 ± 0.1°C in 90% (v/v) DMSO-water solution containing 1.0 mM metal ion or 1 mM ligand 3 while the metal-to-ligand ratio was varied between 1:1 and 1:3. Ionic strength was 10 mM (TBACl). Measurements were performed on a conventional three-electrode system under argon atmosphere and a PC controlled Electrochemical Measurement System (EF 451). Samples were purged for 15 min with argon before recording the cyclic voltammograms. A glassy carbon electrode was used as the working electrode, a platinum electrode as the auxiliary electrode and Ag/AgCl/KCl (1 M) as reference electrode.
Electrochemical potentials were converted into the normal hydrogen electrode (NHE) scale by adding 0.236 V [33] . The electrochemical system was calibrated with a solution of ferrocene in 90% (v/v) DMSO-water (E 1/2 = +0.428 ± 0.012 V vs. Ag/AgCl/KCl (1 M) in our setup). Redox potentials were obtained at 100 mV/s scan rate in the range of −1.2 to +1.0 V.
Oxidation of ascorbic acid (ASC) and glutathione (GSH)
Oxidation of ASC and GSH by the copper(II) and iron(III) complexes of ligand 3 was studied by UV-Vis spectrophotometry using a Hewlett Packard 8452A diode array spectrophotometer. A special, tightly closed tandem cuvette (Hellma Tandem Cell, 238-QS, path length: 1 cm) was used and the reactants were separated until the reaction was triggered. Both isolated pockets of the cuvette were completely deoxygenated by bubbling a stream of argon for 10 min before mixing the reactants. Spectra were recorded before and immediately after mixing, and changes were followed for maximum of 90 min. One of the isolated pockets contained the reducing agent (ASC or GSH) at ten times higher concentrations than that of the metal ions. The other pocket contained the metal ions (Cu(II): 25 μM; Fe(III): 50 μM) and ligand 3 at 1:1 metalto-ligand ratio. The pH of the solutions was adjusted to 7.40 (copper complexes) or 5.45 (iron complexes) by 50 mM HEPES or MES buffers, respectively, and an ionic strength of 0.1 M (KCl) was applied at 25.0 ± 0.1°C. At the end of the measurements 30% H 2 O 2 (50 μL) was added to the samples (1.4 mL).
Establishment of transgenic ABCB1 expressing Madin-Darby canine kidney II (MDCKII) cell line
MDCKII-ABCB1 cell line stably expressing the human wild-type MDR1/ABCB1 was established by the Sleeping Beauty transposonbased gene delivery system, using the 100× hyperactive SB transposase [34] . MDCKII canine kidney cells were cotransfected with the SB transposon vector containing the wild-type human MDR1 cDNA [35] and the SB transposase vector construct, using the Lipofectamine 2000 reagent (Life Technologies) in accordance with the manufacturer's instructions. Briefly, 3 × 10 5 cells were seeded in 6-well-plates; 24 h later the cells were transfected with 2 μg vector DNA per well in a 10:1 ratio for the SB transposon and transposase constructs. 48 h after transfection transgene positive cells were sorted by flow cytometry (FACS Aria High Speed Cell Sorter, Beckton-Dickinson) based on the cell surface expression of wild-type and mutant MDR1/ABCB1. Protein expression was measured by antibody labeling using the human MDR1/ABCB1 specific monoclonal antibody MRK16 (Abnova). To obtain homogenous transgene positive cell population, sorting procedure was repeated 4 times in 2-week intervals.
Vector constructs
Sleeping Beauty (SB) transposon vector carrying the wild-type human MDR1 cDNA was constructed as follows. The SB transposon vector containing the cDNAs of EGFP and the puromycin resistance gene (PURO) in separate transcription cassettes, each driven by CAG promoter, was kindly provided by Dr. Tamás István Orbán (Hungarian Academy of Sciences, Budapest, Hungary) [36] . Full-length wild-type MDR1 cDNA was amplified by PCR from pAcUW-LMDR1 vector [37] with the following primers: 5′-TAGAATACCGGTAGGTCGGAATGGATCT TGAA-3′ and 5′-AGTGATGGATCCAACATCTCATACAGTCAGAG-3′ containing AgeI and BamHI restriction sites, respectively. The digested PCR product was cloned into the SB-EGFP-PURO transposon vector between the AgeI and BclI restriction sites, replacing EGFP, resulting in SB-MDR1-PURO vector.
Cell culture
The human ovarian carcinoma cell lines A2780 and the doxorubicin selected multidrug resistant counterpart A2780adr were obtained from ECACC, UK ( Gottesman, National Institutes of Health) were cultivated in DMEM. The phenotype of the resistant cells was verified using cytotoxicity assays (not shown). MDCK II and the Pgp transfected MDCK-B1 were cultured in DMEM. DMEM media (SigmaAldrich, Hungary) were supplemented with 10% fetal bovine serum, 5 mmol/L glutamine, and 50 units/mL penicillin and streptomycin (Life Technologies). All cell lines were cultivated at 37°C, 5% CO 2 .
MTT viability assay
MTT viability assays were performed as described earlier with minor modifications [38, 39] . Briefly, cells were seeded into 96-well tissue culture plates (Sarstedt, Newton, USA/Orange, Braine-l'Alleud, Belgium) in the appropriate density evaluated for each cell line (5000 cells per well for MES-SA-Dx5 and KB-3-1/v1 cells, 10,000 cells per well for A2780 cells) and allowed to attach for 12 h. Test compounds were added to achieve the required final concentration in a final volume of 200 μL per well. After an incubation period of 72 h, the supernatant was removed and fresh medium supplemented with the MTT reagent (0.083 mg/mL) was added. Incubation with MTT at 37°C was terminated after 1 h by removing the supernatants and lysing the cells with 100 μL DMSO per well. Viability of the cells was measured spectrophotometrically by absorbance at 540 nm using either a Perkin Elmer Victor X3 or a BMG POLARstar microplate reader. Data was background corrected by subtraction of the signal obtained from unstained cell lysates and normalized to untreated cells. Curves were fitted by Prism software [40] using the sigmoidal dose-response model (comparing variable and fixed slopes). Curve fit statistics were used to determine the concentration of test compound that resulted in 50% toxicity (IC 50 ).
ROS determination using DCFDA
Measurements were performed as reported in the literature with modifications [41] [42] [43] . After harvesting and washing with phosphate buffered saline (PBS), cells were incubated with 10 μM DCFDA in a water bath shaker at 37°C for 30 min in a density of 3 Mio cells/mL. After washing with PBS cells were seeded to 96 well plates in PBS in a density of 20,000 cells/well. Basal fluorescence was measured; after addition of the test compounds in different concentrations samples were measured in time intervals of 10 min. DCFDA solution in buffer was used as a cell free control to test for interaction of the test compounds with DCFDA. Data was analyzed as fold change of fluorescence compared to the basal levels.
Results and discussion

Synthesis
As depicted in Scheme 1, the pyrimidinylhydrazones 1 to 3 were prepared by reacting 4-hydrazinyl-6-methoxypyrimidine (derived from 4,6-dichloropyrimidine) with equimolar amounts of the respective keto component under mild acidic conditions. While compound 1 serves as the non-alkylated core structure, 2 possesses an ethyl group as substituent in the aromatic ring and 3 has a methyl group at the imino carbon. 5-Ethylpicolinaldehyde used for the synthesis of 2 was prepared following the method patented by Seydel et al. in a slightly modified manner [15] . After formation of the N-oxide from 5-ethyl-2-methylpyridine using hydrogen peroxide in glacial acetic acid, followed by alkaline reconditioning, an acetoxy group was introduced using acetic anhydride, glacial acetic acid to provide 5-ethylpyridin-2-yl-methyl acetate. The cleavage of the ester to the corresponding alcohol was carried out in THF, as the suggested conditions using ethanol as a solvent provided the ethyl ether instead. The oxidation to the desired aldehyde required a long time; and reflux with freshly prepared MnO 2 under ultrasound was found to be an efficient oxidizing method. Several other methods including commercially available MnO 2 [15] , the application of SeO 2 and tert-butyl hydroperoxide [44] , or the attempt to directly oxidize the 5-ethyl-2-methyl-pyridine [45] [46] [47] were not successful. With the help of the modifications in the first and in the last steps of the original approach, the yield could be increased from the reported 18% to 40%.
Physico-chemical properties are known to influence pharmacokinetics and pharmacodynamics; therefore we were interested in the lipophilicity of the three compounds. Since the lipophilicity of the compounds was too high to allow the exact determination of logD 7.4 values by the traditional shake flask method in n-octanol/buffered aqueous solution (1:1), logD 7.4 values were estimated using MarvinSketch [48] and the relative lipophilicity of the compounds was determined using HPLC. This method is commonly used for the determination of log K w (log P) [49] . We used an isocratic method to measure the retention times of the neutral forms of the compounds as a function of the organic composition of the eluent. Results of five different eluent compositions (summarized in Supplementary Table A1) were used for the accurate determination of the log k values as described in the Materials and methods section. Since in this setup the retention coefficients of the three analytes show linear correlation with the volume fractions of the organic solvent in the binary eluent, the relative lipophilicity of the compounds was determined using the linear solvent strength model [49] . The resulting log K w values are shown in Table 1 .
Characterizing the in vitro antiproliferative activity of compounds 1 to 3
The cytotoxic potency of pyrimidinylhydrazones 1 to 3 was investigated in a diverse panel of cancer cell lines including A2780 (ovarian carcinoma cells), KB-3-1 (cervix carcinoma) and MES-SA (uterine sarcoma). To test the ability of the newly synthesized compounds to overcome drug resistance, resistant derivatives of the cell lines (A2780adr, KB-v1 and MES-SA-Dx5) were also included in the study. Resistance of these cell lines is primarily mediated by the overexpression of Pgp, which effluxes structurally and mechanistically unrelated cytotoxic compounds from the cells [50] [51] [52] . To clearly delineate the effect of Pgp on the toxicity of the compounds, we included control MDCK-II and its drug resistant derivative MDCK-II-ABCB1 engineered to overexpress cDNA-derived Pgp.
As summarized in Table 2 , the three tested compounds proved to be toxic in all investigated cell lines (with IC 50 values of 0.03-6.30 μM) regardless of their resistance status towards common cytostatic agents. Toxicity of the compounds does not correlate with lipophilicity ( Table 1) . Alkylation of 1 resulted in increased toxicity in all eight investigated cell lines. Introduction of a methyl at the imino carbon, as in 3 increases toxicity to a higher extent as compared to the introduction of an ethyl group at the aromatic ring as in compound 2.
Proton dissociation processes of ligand 3
Since the physico-chemical properties of a potential chemotherapeutic agent have a basic influence on its pharmacokinetics and metal binding abilities, a detailed study on the proton dissociation processes of the most promising compound 3 was performed. For this purpose UV-Vis spectrophotometric titrations were applied at a concentration of 50 μM (in the presence of 0.5% (v/v) DMSO). The recorded pHdependent spectra (Fig. 1a) revealed two proton dissociation processes at pH b 9; the calculated protonation constants (logβ(H i L)) and pK a values are reported in Table 3 . The spectra for the individual ligand species in different protonation forms (H 2 L 2+ , HL + and L) were calculated by the deconvolution of UV-Vis spectra recorded at different pH values (Fig. 1b) 
, which are assigned to n → π* transitions. The determined pK a values demonstrate that the proton dissociation processes overlap and the neutral form L predominates in the physiological pH range as illustrated in Fig. 1c . pK 1 can most presumably be attributed to the deprotonation of the pyrimidinium unit, while pK 2 belongs to the deprotonation of the pyridinium-N as shown in Scheme 2. Deprotonation of the pyridinium moiety in the case of the α-Npyridyl thiosemicarbazones such as the drug Triapine was also shown to result in similar spectral changes, namely a significant shift of λ max value from 402 nm to 368 nm [53] . The possible proton dissociation of the hydrazinic = N-NH group of ligand 3 is likely to take place at higher pH values (pH N 11) and therefore its pK a could not be determined accurately with the applied method.
Complex formation processes of ligand 3 with Fe(III) and Cu(II)
The biological activity of metal binding compounds is often modified upon complex formation with metal ions [18, 54] . Characterization of metal binding ability (solution speciation), and the most plausible chemical species formed in aqueous solution in the biologically relevant pH range is a mandatory prerequisite for understanding the mechanism of action of complexes. To this end, we determined the stoichiometry and stability of ligand 3 complexes formed with Fe(III) and Cu(II) in aqueous solutions using UV-Vis spectrophotometry. The stoichiometries of the metal complexes and the overall stability constants furnishing the best fits to the experimental data are listed in Table 4 . The appearance of well-defined charge transfer (CT) bands in the visible wavelength range of pH-dependent UV-Vis spectra unequivocally showed complex formation with both metal ions (Figs. 2 and 3 ). These CT bands overlap considerably with the ligand bands, while the d-d bands are too weak to be detected under the Fig. 2 ), although the hydrolysis of the metal ion suppresses the complex formation at pH N 8. 5 . Surprisingly, the development of CT bands that are characteristic for Fe(II) complexes formed with ligands consisting of aromatic nitrogen donor atoms was also detected at pH N~8.5 in the 510-610 nm wavelength range. Formation of minor amounts of iron(II) complexes is possible at lower pH values as well. The redox process of the complex seems to be pH-dependent and much faster in the basic pH range. Thus data collected at pH N 7.5 were not evaluated. In order to compare the iron binding ability of ligand 3 with that of other well-known iron chelators, the pM value (=− log [Fe(III)]; c L /c M = 10; c M = 1 μM) was calculated at physiological pH, using the experimentally determined stability constants. For Fe(III) a pM value of 17.6 was obtained, which is lower than those reported for the naturally occurring iron binders such as human serum transferrin (20.3) [55] , desferrioxamine B (26.5) [56] or the chelator Deferiprone (19.3) used to treat thalassemia major [57] , but is higher than the pM value of the thiosemicarbazone drug Triapine (15.7) [58] . Since higher pM values imply that metal complex formation is more favored, these results suggest that the studied pyrimidinylhydrazone forms less stable complexes compared to the aforementioned chelators containing mainly oxygen donor atoms. However, the Fe(III) binding ability of ligand 3 can exceed that of the tridentate α-N-pyridyl thiosemicarbazones with a (N pyridyl ,N,S − ) binding mode at pH 7.4. In the case of the Cu(II) ion, the formation of mono-ligand complexes was expected due to the usual square planar geometry of the Cu(II) coordination sphere, although the speciation model was significantly improved by the involvement of bis-ligand [CuL 2 ] 2+ species (see Fig. A1 ). Deconvolution of the UV-Vis spectra recorded in the Cu(II)-ligand 3 system yielded the formation constants summarized in In order to compare the Cu(II) and Fe(III) binding ability of ligand 3, the pM value was also computed on the basis of the stability data (conditions: pH = 7.40; c L /c M = 10 μM; c M = 1 μM) and a value of 8.6 was obtained for Cu(II). Since Fe(III) tends to hydrolyze at physiological pH, its hydroxido species were also taken into account and a modified pM value (pM*) was determined for Fe(III), by calculating the negative logarithm of the summed equilibrium concentrations of the free metal ion and its hydroxido species (pM* = − log ([Fe] + Σ[Fe p (OH) r ])). pM* for Fe(III) was computed to be 9.5, which is almost one order of magnitude higher than the pM of Cu(II). At an acidic pH (5.45) pM* can be considered equal to pM, due to the lower extent of hydrolysis, therefore values of 8.5 and 13.3 were computed for the Cu(II) and Fe(III) complexes, respectively. These results indicate that whereas ligand 3 forms stable complexes with both Fe(III) and Cu(II), the unbound metal fraction is somewhat higher in the case of Cu(II) showing the stronger Fe(III) binding ability of ligand 3 under physiological conditions and in the slightly acidic pH range as well.
Effect of the metal ions on the toxicity of ligand 3
Having shown the strong metal binding ability of ligand 3 to Fe(III) and Cu(II), experiments were designed to evaluate the impact of metal ions on its toxicity. Ligand 3 was added to the parental MES-SA cells and its resistant derivative MES-SA-Dx5 with increasing concentrations of metal ions. The metal salts alone had no impact on cell viability over a three day long incubation period; therefore additive effects could be excluded. In MES-SA cells, coincubation of 3 with Fe(III) was found to reduce the ligand's cytotoxicity, while the presence of Cu(II) had an opposite effect (Fig. 4) . Interestingly, the effects of both metal ions, namely the rescuing by iron and the sensitization by copper was found to be significantly attenuated in MES-SA-Dx5 cell line, the drug resistant derivative of MES-SA.
Reduced activity of the free ligand in the presence of the iron indicates that the toxicity may -at least in part -be explained by the depletion of cellular iron levels. The differential sensitivity of the drug resistant subline is reminiscent of the collateral sensitivity of MDR cells [60] . The mechanisms underlying the paradoxical hypersensitivity of resistant cells are not known. It has been suggested, but never shown, that the metal homeostasis of MDR cells is altered as a result of Pgp function. Lack of the protective effect of Fe(III) in the MDR subline suggests that these cells cannot be rescued by excess iron -perhaps due to the imbalanced iron homeostasis of MDR cells.
In follow up experiments the Cu(II) and Fe(III) complexes of ligand 3 were prepared in situ by mixing the ligand with half-and one equimolar concentrations of the metal ions. Using this setup a constant molar ratio was ensured throughout the investigated concentration range (1 nM-250 μM). Results obtained in the presence of increasing metal ion concentrations at a fixed ligand-to-metal molar ratio confirmed the reduced toxicity of Fe(III) complexes (not shown), while the effect of Cu(II) was less pronounced in that setup as compared to the coincubation (Fig. 7) .
Cyclic voltammetric studies of Fe(III) and Cu(II) complexes of ligand 3
Besides depleting metal ions, the mechanism of toxicity of chelating compounds also relies on redox active complexes that may be formed in the Fenton reaction [1, 7, 41] . To examine the redox properties of the iron and copper complexes of ligand 3, we performed cyclic voltammetry (CV) studies and the measured formal potentials were compared to those of Triapine and physiological reductants. of − 0.9 to + 1.0 V against Ag/AgCl/KCl (1 M). Ligand 3 alone was found to be redox-innocent in this range. It should be noted that the ligand alone shows an irreversible process resulting in a cathodic peak seen at~− 1.01 V vs. Ag/AgCl/KCl (1 M) (which corresponds to − 0.78 vs. NHE, Fig. A3 ). The complexes of both metal ions showed redox activity. The redox potential of the formed complexes is largely controlled by the donor atoms of the ligand that are present in the first coordination shell. The addition of the chelating agent significantly changed the peak positions in comparison to those of the aqua complexes. The detected redox processes for the Fe(III)/Fe(II) and Cu(II)/Cu(I) couples were found to be quasi reversible under the applied conditions in all cases (for a detailed analysis of CV data see Table A2 ).
Addition of ligand 3 to Fe(III) results in the formation of a metal complex and the appearance of a new set of peaks in the voltammograms at~+0.68 V vs. NHE as calculated from the measured data represented in Fig. 5a . Upon complexation the formal potential increased by 0.31 V; the intensity of the aqua ion peaks decreased, while that of the metal complex increased with increasing ligand excess. The positive shift of the formal potentials due to the coordination by the ligand via (N pyridyl ,N hydrazone ,N pyrimidyl ) donor set indicates a preference for the lower oxidation state, as in the case of other well-known ligands consisting of aromatic nitrogen donor atoms such as 2,2′-bipyridyl or 1,10-phenanthroline. This can be a possible explanation for the reduction of Fe(III) complexes in the basic pH range (vide supra). The formal potential of the complexed Fe(III)/Fe(II) redox couple is significantly higher (~+ 0.69 vs. NHE) than that of other iron chelators such as Triapine (+0.07 V vs. NHE) [58] or tris-hydroxamato complexes (− 0.43 V) [61] resulting in an easier reduction by physiological reductants.
Ligand 3 also influences the redox potential of the Cu(II)/Cu(I) couple. Addition of the ligand diminished the intensity of the aqua complex peaks, while a new reduction peak appeared upon complexation.
In case of the copper complexes, the formal potential was shifted by 0.25 V to the negative direction, indicating the ligand preference for the metal ion in the higher, +2 oxidation state. The formal potential of the Cu(II)/Cu(I) in the case of ligand 3 (+0.36 V vs. NHE) is higher than that of the biological reductants (glutathione, ascorbate [1, 62] ), thus the reduction of this Cu(II) complex may lead to redox cycling and the generation of ROS.
Reduction of complexes formed with ligand 3 by intracellular reducing agents
In order to further investigate the potential of the copper and iron complexes formed with ligand 3 to undergo intracellular redox reactions, the ability of biologically relevant reducing agents such as ascorbate (ASC) or glutathione (GSH) to reduce the complexes was tested in in vitro assays. The redox processes were followed spectrophotometrically under strictly anaerobic conditions via monitoring the overlapping ligand and CT bands in the wavelength range of 300-600 nm. Kinetic runs were performed at pH 7.40 in the case of the copper complexes, while pH 5.45 was chosen for the iron Table 4 Overall stability and stepwise constants of Fe(III) and Cu(II) complexes of ligand 3 together with the λ max (nm) / ε (M −1 cm −1 ) values of the individual species {t = 25.0°C, complexes in order to avoid metal ion hydrolysis and the possible formation of the Fe(II) species in the Fe(III)-ligand 3 system in the basic pH range (see Section 3.3). Oxidation of ASC yields dehydro-L-ascorbic acid; the oxidized form of GSH is glutathione disulfide (GSSG). Neither the reduced and oxidized form of ASC nor GSH absorbs light at λ N~310 nm [63] , thus spectral changes above this wavelength are characteristic only to the absorption of the metal complexes. Oxidation of ASC or GSH is often monitored at their λ max values (265 and 262 nm, respectively) [9, 64] , but since the studied metal complexes, as well as the free ligand 3 absorb light strongly in the UV range, the UV-Vis spectra were recorded between λ~300 nm and 600 nm upon addition of ASC and are shown in Fig. 6 . No time dependent spectral changes were observed (t max = 75 min) in the case of the Cu(II) complexes (Fig. 6a) , which suggests that this metal complex could not be reduced by ASC under the applied conditions. We also monitored the spectral changes of the formed complexes upon reduction by GSH (Fig. 6c) . Glutathione is a predominant intracellular reducing agent with a lower formal potential compared to that of ASC. (The formal potential at pH 7.4 of the GSSG/GSH and the dehydro-L-ascorbic acid/ASC redox pairs are − 0.26 V and + 0.05 V, respectively [62, 65] .) In the case of copper a significant decrease of the absorbance was observed at the λ max value of the Cu(II) complex (408 nm) during the redox reaction; while the absorbance value was increased at the λ max of the free ligand (~310 nm), most probably as a result of the decomposition of the generating instable Cu(I) complex. These results suggest that the stronger reducing agent GSH is able to reduce the Cu(II) complex. Addition of H 2 O 2 regenerated the Cu(II) complexes, suggesting that a reversible redox process can contribute to the toxicity of the compound.
In line with the high redox potential of the Fe(III)-ligand 3 complex (see Section 3.6), this complex was reduced by ASC (Fig. 6b) ; yet the redox reaction was relatively slow. When H 2 O 2 was added to the sample at the end of the kinetic run only negligible spectral changes were observed even after 0.5 h, suggesting that the iron complex is not likely to undergo intracellular redox cycling.
Surprisingly, ten-fold excess of GSH resulted in almost no changes in the UV-Vis spectrum of the Fe(III)-ligand 3 system (Fig. 6b) within 90 min, suggesting that the kinetic of the reduction is fairly slow. A similar trend was observed in the reduction kinetics of vanadium complexes by the two reducing agents [63, 64] . Furthermore, the formal potentials of both reducing agents are pH-dependent, which might also explain the lack of GSH-induced reduction of the iron complex at pH 5.45. Based on studies on the pH dependence of the redox potentials, it can be estimated that at pH 5.45, the redox potential of GSH and ASC are shifted by 116 mV and 52 mV, respectively [62, 65, 66] .
Taken together, our results indicate that the Cu(II) complex of ligand 3 has the potential to undergo redox-cycling reactions under physiological conditions, whereas the iron complex is probably not able to undergo intracellular redox cycling.
Involvement of ROS in the toxicity of 3
To evaluate the role of ROS production in the toxicity of 3, the cytotoxicity experiments were repeated in the presence of the antioxidant NAC. Coincubation with NAC resulted in a significant increase of the IC 50 values (Fig. 7) , suggesting that ROS play a role in the toxicity of ligand 3. Due to the relative redox potentials a direct reduction of compound 3 by NAC is unlikely; therefore a more probable source of ROS induction is the intracellular formation of redox active complexes undergoing Fenton-like chemistry. In the next set of experiments Cu(II) complexes of ligand 3 were coincubated at 1:1 and 1:2 metalto-ligand ratios with NAC and cytotoxicity was measured in MES-SA and MES-SA-Dx5 cells. Since complexation with Fe(III) significantly attenuates the toxicity of ligand 3, the effect of NAC on the toxicity of the iron complexes could not be reliably determined.
As expected, NAC diminished the toxicity of the Cu(II) complexes, suggesting that ROS may, at least in part, be responsible for the toxicity of the ligand and its metal complexes (Fig. 7c) . Intriguingly, the (relative) protective effect of the antioxidant appeared to be more pronounced in drug resistant cells as compared to their sensitive counterparts (compare A2780adr, Fig. 7b to A2780, Fig. 7a , and dx5 to MES-SA, Fig. 7c ). To characterize the extent of ROS formation, intracellular ROS were measured using the ROS-sensitive cell permeable dye DCFDA. MES-SA and MES-SA-Dx5 cells were preincubated with DCFDA and the effect of ligand 3 and its complexes on fluorescence was evaluated following an 80 minute-long incubation period. Fig. 8 2+ complex was not redox active (Fig. 8a) . In all cases, ROS induced by the metal complexes could be scavenged by the addition of NAC. A similar pattern was observed at 100 μM ligand concentration (Fig. 8b) . Unexpectedly, addition of the ROS scavenger NAC to 100 μM of the [CuL] 2+ complex increased, rather than decreased ROS production. Since this effect could also be observed in the cell free condition, we speculate that the paradoxical effect of NAC is explained by the ability of the complex to participate in redox cycling as a result of the reduction by NAC (see also Figs. 5b, 6c) . The Fenton-like reaction results in increased ROS production, but direct oxidation of DCFH may also contribute to the observed signal [67, 68] . Induction of ROS by NAC was only observed at 100 μM ligand concentration, which is between 300 and 1000 times higher than the IC 50 values obtained in the toxicity studies displayed in Fig. 7c . At [CuL] 2+ ≤ 50 μM, addition of NAC protects against the formation ROS (Fig. 8a ), in line with the protective effect of NAC against the toxicity of compound 3 even in combination with copper (Fig. 7c) .
Evaluation of the toxicity of ligand 3 in MDR cells
Chelators that bypass resistance mechanisms are promising candidates for anticancer drug development [8, 69] . ABC transporters contribute significantly to the multifactorial phenomenon of MDR [70] [71] [72] . As a strategy to overcome Pgp-mediated MDR, several inhibitors have been developed [73, 74] . Despite promising in vitro results, successful translation of MDR transporter inhibition to the clinic remains elusive [75] [76] [77] . Hence there is an urgent need for novel chemotherapeutics with marked and selective antitumor activity, particularly those that can overcome resistance to established therapies. Several chelators have been reported to overcome or even exploit MDR [8, 69] . The toxicity pattern of the newly synthesized (Table 2) , suggests that these compounds are not susceptible to Pgp-mediated efflux. Interestingly, compound 3 shows enhanced activity towards the Pgp expressing MES-SA-Dx5 and A2780adr derivatives. Paradoxical toxicity towards otherwise resistant cells was observed in the case of several chelators, as for the thiosemicarbazone NSC73306 [69] . Intriguingly, the toxicity of the so-called MDR-selective compounds is increased, rather than attenuated by the activity of efflux transporters such as Pgp [60, 69, 78] . To determine the role of Pgp in the increased sensitivity of MDR cell lines to compound 3, cytotoxicity measurements were repeated in the presence of the Pgp-inhibitor TQ or WK-X-24 ( Fig. 9 ) [73, 74] . Inhibition of Pgp did not influence the toxicity of the compounds, suggesting that the observed hypersensitivity of the cells is linked to other factors than Pgp.
Conclusions
There is a continuous demand for the development of novel types of antitumor agents especially with the potential to overcome multidrug resistance. In this work three new pyrimidinylhydrazone Schiff bases were synthesized and characterized, and their antitumor potential and putative mechanism of action were evaluated. The cytotoxicity of the compounds was studied in a panel of human cancer cell lines and the canine MDCK-ABCB1 that was explicitly engineered to evaluate the effect of Pgp, the ATP-dependent pump responsible for the efflux of a broad spectrum of cytotoxic agents. The three tested compounds proved to be cytotoxic in the micro-to submicromolar range, regardless of the resistance status of the cells. Methylation of the core structure at the imine carbon resulted in the most active compound among the studied derivatives (3), since it seemed to increase the toxicity to a higher extent than the introduction of an ethyl-substituent in the pyridine-moiety.
Due to the metal binding ability of ligand 3, its biological activity is likely to be mediated via the formation of complexes with essential metal ions. The high stability of the Fe(III) complex together with a protecting effect upon coincubation with the metal ion suggests that the mechanism of action might be partly mediated by iron depletion. Stable complex formation was also observed with Cu(II). While the complexes of both metal ions show redox activity in cyclic voltammetry measurements, only the Cu(II) complex showed reversible redox cycling in biological relevant conditions (GSH reduction followed by H 2 O 2 oxidation). Intracellular redox cycling of metal complexes might result in ROS formation (Fig. 10) . A similar mechanism ("activation by reduction") has been suggested to explain the enhanced toxicity of other copper complexes compared to their free ligands by Kowol et al. [41] .
Protection from compound-induced cell death by coadministration of the potent ROS scavenger NAC supports this theory. ROS production induced by the metal complexes of ligand 3 was supported by the ROS-sensitive DCFDA fluorescence assay. Green arrows depict reactions catalyzed by the copper-containing superoxide dismutase enzyme [41] , the red arrow represents the Fenton reaction [1] ; the blue arrows represent the redox cycling of the metal ions, which can be activated by the reduction through antioxidants such as glutathione or NAC.
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